In guidelines developed by the European Society of Cardiology, in collaboration with the European Respiratory Society, updated recommendations are presented for the management of patients with acute pulmonary embolism.
Treatment with the next-generation potent prostacyclin receptor agonist ralinepag reduced pulmonary vascular resistance compared with placebo in patients with symptomatic pulmonary arterial hypertension.
Patients who received thrombolysis during cardiopulmonary resuscitation for out-of-hospital cardiac arrest with confirmed pulmonary embolism had significantly higher 30-day survival rates vs patients who did not receive thrombolysis.
A 65-year-old woman with breast cancer and hypertension has been experiencing progressive dyspnea on exertion after complications from chemotherapy.
Researchers gauged the effect of concomitant pulmonary hypertension on clinical outcomes and late-onset progression of tricuspid regurgitation after mitral valve relapse for rheumatic mitral stenosis.
Investigators provide recent information on the classification, pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension, focusing specifically on its impact on women.
This pharmacokinetic substudy was conducted to determine the actual pharmacokinetic profiles of treprostinil in patients transitioning from stable twice daily to stable thrice daily dosing regimens.
An implantable hemodynamic monitor safely monitored hemodynamic changes in patients with severe pulmonary arterial hypertension.
Patients with chronic thromboembolic pulmonary hypertension had increased plasma concentrations of osteopontin, which may be involved in fibrotic remodeling.
Early prophylactic placement of a vena cava filter compared with no placement of a filter after major trauma does not result in a reduced incidence of symptomatic pulmonary embolism or death at 90 days.